Theramex has acquired the commercial rights to Zoely, a patented oral contraceptive, from MSD, the trade name of Merck & Co., Inc., Kenilworth, NJ, USA. Theramex currently markets Zoely in eleven European countries, and this transaction will expand its reach to over 50 markets worldwide. MSD will retain the rights in the United States and Canada.
Zoely is a combined oral contraceptive pill containing two steroid hormones: 17-beta-estradiol, an estrogen structurally identical to the main estrogen produced by the ovaries of healthy, non-pregnant women, and nomegestrol acetate, a progestin that mimics naturally occurring progesterone in the body.
Theramex is a leading global specialty pharmaceutical company dedicated to women's health. With a broad portfolio of innovative and established brands in contraception, fertility, menopause, and osteoporosis, Theramex supports women at every stage of life. Our vision is to be a lifelong partner to women and the healthcare professionals who treat them by providing innovative, effective solutions that care for and support women throughout their lives. To learn more about Theramex, please visit www.theramex.com.
Anish Mehta, CEO of Theramex, stated, "Zoely is one of Theramex's flagship products, so we are delighted to have acquired further rights from MSD. This is another exciting milestone in our global expansion and further evidence of our commitment to patients by building on our portfolio of innovative treatment options for women."
ConAlliance is a leading M&A advisory firm specializing in comprehensive support for company sales and acquisitions within the healthcare sector. Since its founding in 2011, ConAlliance has successfully completed over 100 mandates.
ConAlliance's expertise is entirely focused on corporate transactions in the healthcare sector. Core competencies include medical technology, medical devices, pharmaceuticals, nursing and hospital care, healthcare IT, and other manufacturing and service companies in the global healthcare industry. Healthcare real estate is also part of ConAlliance's extensive portfolio.
For more information about ConAlliance, please visit www.conalliance.com.